Board of Directors

Karen Pignet-Aiach

Ms. Karen Pignet-Aiach is Chair of Lysogene’s Board of Directors

Founder and CEO of Lysogene, Ms. Karen Pignet-Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. From 2008 to 2009, Ms. Karen Pignet-Aiach served as a Member of the Pediatric Committee at the European Medicines Agency (EMA), established in accordance with the European Pediatric Regulation, as a patient representative. In 2008, she also served on the French Ethical Review Board CCPPRB at Ambroise Paré Hospital. Ms.Karen Pignet-Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases such as Alliance Sanfilippo and Eurordis, where she served on the board as treasurer from 2010 to 2011. She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC).

Ms. Karen Pignet-Aiach graduated from the ESSEC Business School and majored in Economics from Institut d’Études Européennes of University Paris.

Carole Deffez

Carole Deffez is a non-Executive, independent member of Lysogene’s Board of Directors.

Carole Deffez began her career at the Institute for International Research, where she headed the Healthcare Division from 1997 to 2000, before joining Spencer Stuart as Life Sciences Senior Associate. In 2006, she became Head of the Life Sciences practice at Leaders Trust, an international executive search firm. In 2010, she joined Heidrick & Struggles as a Partner before co-founding Way Wise in 2014, a consulting firm specialized in management and corporate governance issues. In September 2015, she joined Heidrick & Struggles again as a Partner.

Carole Deffez graduated of the IEP Toulouse in Political Sciences and subsequently earned a post-graduate degree in Business Administration from IAE. She attended the University of Missouri, Columbia in the United States for one year before completing her Masters’ degree in Marketing Management at ESSEC (Paris).

David Schilansky

Mr. David Schilansky is a non-Executive, independent member of Lysogene’s Board of Directors.
David Schilansky is currently co-founder and CEO of Home Biosciences, the first venture builder dedicated to biotech in Europe. He has also co-founded One Biosciences, a company focused on generating precision medicines by leveraging the power of single-cell  technologies. David has more than twenty years of professional experience, mainly in the pharmaceutical and biotechnology industry. From 2011 to 2019, he co-headed DBV Technologies, in charge of Finance & Strategy, where he notably led two IPOs on Euronext and Nasdaq, raising more than one billion US dollars in total. David began his career as an investment banker in M&A at UBS Warburg. He worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group Chief Financial Officer, before moving to DBV. David Schilansky received a master’s degree from Université PSL Dauphine and a post-graduate degree from Imperial College London.

Mathieu Simon

Dr. Mathieu Simon is a non-Executive, independent member of Lysogene’s Board of Directors.

A graduate in internal medicine from the Faculty of Medicine of Paris VII, Dr. Simon is Senior Strategic Advisor at Messier Maris & Associés, an international investment bank. He is also an independent Director of Vaximm AG, LNC SA, member of the Supervisory Board of Affimed and non-executive member of Idorsia Board of Directors. Moreover, Dr. Simon is an advisor to the European Commission – Research and Innovation. He previously held positions of Executive Vice President, Chief Operating Officer of Cellectis, CEO of Cellectis Therapeutics and CEO of Ectycell; Senior Vice President and Head of Global Pharmaceutical Operations at Pierre Fabre SA, as well as general management and senior corporate roles at Wyeth Pharmaceuticals. He was also Chairman of the Board of Directors of Cellartis AB.

Peter Lichtlen

Dr. Peter Lichtlen is a non-Executive, independent member of Lysogene’s Board of Directors.

Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc. until the company’s acquisition by Mallinckrodt Pharmaceuticals earlier this year and has 18 years of leadership experience in the field of biotechnology.
Prior to joining Sucampo, Dr. Lichtlen was at ESBATech AG (acquired by Alcon/Novartis in 2009), which he joined in 2000. At ESBATech, Dr. Peter Lichtlen served as Medical Director/Head Clinical Research and Development and was a member of its senior management team, from 2004 to 2010. Dr. Peter Lichtlen also co-founded Numab AG, a Swiss biotechnology company that develops antibody-based therapeutics, where he remains a member of the Board of Directors and Chief Medical Officer. Dr. Peter Lichtlen also currently serves on the scientific advisory board of Apidel SA, a drug delivery company.

Dr. Peter Lichtlen is a member of the Swiss Medical Association (FMH) and the Swiss Association of Pharmaceutical Professionals (SwAPP), the author of various peer-reviewed articles, and the holder of several patents.

Dr. Peter Lichtlen earned a Bachelor’s Degree in business administration, and doctorate degrees in medicine and molecular biology at the University of Zurich.

Philippe Goupit

Dr. Philippe Goupit is a non-Executive, independent member of Lysogene’s Board of Directors.

Dr. Philippe Goupit graduated from the Paris School of Pharmacy and held several key positions in sales, marketing and regulatory affairs at Servier and then at Pasteur in the vaccines sector. Subsequently, he was appointed VP, Mergers & Acquisitions at Sanofi, a global leader in the healthcare sector. He was also Head of Investor Relations at the Sanofi group for several years. Dr. Philippe Goupit currently sits on the Board of Directors of MedDay Pharmaceuticals, a pioneer in developing therapies for central nervous system disorders.

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.